Multimodal Treatment of Advanced Mucosal Melanoma in the Era of Modern Immunotherapy

Cancers

Pietro Quaglino¹  Umberto Ricardi²  Serena Badellino³  Anna Szumera-Ciećkiewicz⁴  Slawomir Falkowski⁵  Pawel Teterycz⁵  Piotr Rutkowski⁵  Pawel Rogala⁵  AnnaM. Czarnecka⁵  MateuszJ. Spałek⁵  Bożena Cybulska-Stopa⁶  Mario Mandala⁷  Alice Labianca⁷  Alice Indini⁷ 

[1] Department of Medical Sciences, Dermatologic Clinic, University of Turin, 10126 Turin, Italy;Department of Oncology, Radiation Oncology, University of Turin, 10126 Turin, Italy;Department of Oncology, Radiotherapy Unit, AOU Città della Salute e della Scienza di Torino, 10126 Turin, Italy;Department of Pathology and Laboratory Medicine Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, 02-781 Warsaw, Poland;Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland;Maria Skłodowska-Curie National Research Institute—Oncology Center, Krakow Branch, 31-115 Krakow, Poland;Melanoma Unit, Department of Oncology and Hematology, Papa Giovanni XXIII Hospital, 24127 Bergamo, Italy;

关键词: mucosal melanoma;    nivolumab;    pembrolizumab;    ipilimumab;    radiotherapy;   

DOI  :  10.3390/cancers12113131

来源: DOAJ

【 摘 要 】

Mucosal melanoma is a rare disease epidemiologically and molecularly distinct from cutaneous melanoma developing from melanocytes located in mucosal membranes. Little is known about its therapy. In this paper, we aimed to evaluate the results of immunotherapy and radiotherapy in a group of patients with advanced mucosal melanoma, based on the experience of five high-volume centers in Poland and Italy. There were 82 patients (53 female, 29 male) included in this retrospective study. The median age in this group was 67.5 (IQR: 57.25–75.75). All patients received anti-PD1 or anti-CTLA4 antibodies in the first or second line of treatment. Twenty-three patients received radiotherapy during anti-PD1 treatment. In the first-line treatment, the median progression-free survival (PFS) reached six months in the anti-PD1 group, which was statistically better than 3.1 months in the other modalities group (p = 0.004). The median overall survival (OS) was 16.3 months (CI: 12.1–22.3) in the whole cohort. Patients who received radiotherapy (RT) during the anti-PD1 treatment had a median PFS of 8.9 months (CI: 7.4–NA), whereas patients treated with single-modality anti-PD1 therapy had a median PFS of 4.2 months (CI: 3.0–7.8); this difference was statistically significant (p = 0.047). Anti-PD1 antibodies are an effective treatment option in advanced mucosal melanoma (MM). The addition of RT may have been beneficial in the selected subgroup of mucosal melanoma patients.

【 授权许可】

Unknown